Navigation Links
Statement by Teva Pharmaceuticals on Eshoo-Barton Bill
Date:3/17/2009

NORTH WALES, Pa., March 17 /PRNewswire-USNewswire/ -- Teva Pharmaceuticals USA, the leading generic pharmaceutical company, today released the following statement by Debra Barrett, Senior Vice President of Government Affairs on the introduction of a biogenerics bill by Representatives Anna Eshoo and Joe Barton:

"In this year of healthcare reform, consumers should rightfully demand better access to affordable medicines. The legislation re-introduced in the House today is clearly written to protect brand-name drugs and their innovator's government-granted monopoly at the expense of access and innovation. This bill will dampen innovation and deny Americans access to more affordable healthcare.

"Congress took a bold step in 1984 when it passed Hatch-Waxman - an effort that led to the greatest explosion of innovative medicines in history - while creating a pathway for more affordable alternatives. We hope that our policymakers will enact legislation that puts the interests of patients above the guarantee of excessive monopoly."

About Teva

Teva USA is a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd., one of the largest generic pharmaceutical companies in the world and among the top 20 pharmaceutical companies. For more information, please visit www.tevausa.com or www.tevadc.com.

    Media Contact: Denise Bradley
    Phone: (215) 591-8974
    E-mail: Denise.Bradley@tevausa.com


'/>"/>
SOURCE Teva Pharmaceuticals USA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Statement by Shelby Knox on the Introduction of the REAL Act
2. Grocery Manufacturers Association Statement Regarding President Obamas Nomination of FDA Commissioner
3. GPhA Statement on Nomination of Dr. Margaret Hamburg as Commissioner and Dr. Joshua Sharfstein as Deputy Commissioner of FDA
4. AJWS Asks International Community to Demand Reinstatement of International Aid Groups Into Sudan
5. Insmed Announces FDA Issues Statement Regarding Position on Allowing Patients With ALS Access to IPLEX(TM) Under an IND
6. Pelosi Statement on President Obamas Executive Order on Stem Cell Research
7. AHIP Statement on White House Health Care Summit
8. Change to Win Statement on White House Health Care Forum
9. Statement by Bruce Bodaken, Chairman & CEO, Blue Shield of California, Regarding President Obamas Healthcare Summit
10. AAJ Statement on Supreme Court Decision in Favor of Diana Levine
11. NJLRA Statement on Todays U.S. Supreme Courts Decision in Wyeth v. Levine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, ... Elite. The attorneys chosen by their peers for this recognition are considered among the ... Traurig Shareholders received special honors as members of this year’s Legal Elite Hall of ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB ... Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards ... in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)...  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas ...
(Date:6/23/2016)... June 23, 2016  Experian Health, the ... transforming the patient payment and care experience, ... new products and services that will enhance ... cycle offerings. These award-winning solutions will enable ... remain compliant in an ever-changing environment and ...
Breaking Medicine Technology: